The US interventional cardiology market will continue to exhibit weak growth in the next five years, but there will be pockets of healthy growth, such as in coronary thrombectomy devices. According to Medtech Insight’s latest report on the sector, growth to 2018 will also be supported by several other factors, including the anticipated introduction of at least one drug-eluting balloon (DEB) catheter for at least one coronary angioplasty indication; the stabilization of coronary stenting volumes and the possibility of the market launch of a bioresorbable stent system near the end of the forecast period; and steady growth in the sale of mechanical atherectomy, transcatheter septal defect repair, and vascular access site repair devices.
In the US, an estimated 83.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?